Latest news with #antibodyDiscovery
National Post
12-05-2025
- Business
- National Post
IPA's LENSai™ Platform Delivers X-Ray–Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater Speed
Article content AUSTIN, Texas — ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ:IPA) a leader in AI-driven biotherapeutics, is pleased to announce today new benchmarking results that validate the accuracy and utility of its in silico epitope mapping application, part of the LENS ai ™ platform, with a direct comparison to gold-standard wet-lab methods. Article content Article content The results represent a notable advancement in computational biology, particularly in the field of antibody discovery, where high failure rates and costly, time-intensive experiments remain common industry challenges. LENS ai 's AI-powered platform was able to match the performance of x-ray crystallography—the industry's most precise but slowest and most expensive method—using sequence data alone. Article content 'In an industry where over 95% of drug candidates fail before reaching the clinic, accelerating decisions earlier in the discovery pipeline isn't a luxury—it's a necessity,' said Dr. Jennifer Bath, CEO of IPA. 'With LENS ai, we're demonstrating that AI is designed to deliver accurate, scalable, and human-relevant biological predictions that were previously only accessible through months of experimental work.' Article content In the benchmarking study, LENS ai 's in silico epitope mapping application was tested across five known antibody-antigen pairs and against multiple experimental techniques, including HDX-MS, alanine scanning, and x-ray crystallography. The AI system produced predictive scores (AUC 0.79–0.89) comparable to or exceeding those achieved by leading wet-lab methods, while reducing turnaround time from weeks to hours. Article content Epitope mapping is a cornerstone of antibody development, informing everything from IP strategy to candidate selection. Traditionally, this requires expensive, time-consuming lab work using scarce protein samples. LENS ai transforms this by delivering early-stage epitope insights from sequence alone, reducing both cost and risk. Article content This breakthrough aligns with growing regulatory and industry momentum around New Approach Methodologies (NAMs), including the FDA's recent decision to phase out animal testing requirements for biologics. By eliminating the need for physical materials and enabling near–x-ray-level precision, LENS ai advances ethical, scalable, and high-resolution approaches to biotherapeutic discovery Article content We view this achievement as a meaningful advancement that enhances the capabilities of drug discovery platforms' added Dr. Bath. 'LENS ai is now capable of providing pharma and biotech partners with validated, in silico answers to questions that once required months of wet-lab commitment.' Article content This latest achievement marks a major step in the broader development of LENS ai, IPA's AI-driven discovery platform. Building on previous releases, including in silico antibody engineering, epitope prediction, and multi-omics integration, LENS ai continues to demonstrate its ability to deliver high-resolution, scalable insights across key stages of biotherapeutic discovery. Today's advancement in epitope mapping reflects the growing power of the platform we have been strategically building — connecting sequence-based precision, accelerated timelines, and deep scientific insight to transform the future of therapeutic development. Article content ImmunoPrecise Antibodies Ltd. is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the discovery and development of therapeutic antibodies and is known for solving complex industry challenges. IPA has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the 'IPA Family'). Article content This press release contains forward-looking statements within the meaning of applicable United States and Canadian securities laws. Forward-looking statements often include words such as 'expects,' 'intends,' 'anticipates,' 'believes,' or variations thereof, or state that certain actions, events, or results 'may,' 'will,' 'could,' or 'might' occur. These statements relate to, among other things, the anticipated benefits, scalability, and adoption of the LENSai platform, the broader application of HYFT®-based tools, the advancement of AI-native drug discovery methods, and the Company's ability to maintain regulatory alignment and commercial traction. Article content Although the Company believes it has a reasonable basis for these forward-looking statements, they are based on current expectations, assumptions, and projections about future events that involve risks and uncertainties. Actual results may differ materially from those expressed or implied due to factors largely beyond the Company's control, including but not limited to scientific and technological developments, regulatory changes and acceptance, competitive dynamics, IP protection, platform integration challenges, and financial and operational risks. Article content Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied herein. Additional information on risks and uncertainties can be found in the Company's Annual Report on Form 20-F, as amended, for the year ended April 30, 2024 (available on the Company's SEDAR+ profile at and EDGAR profile at Should any of these risks materialize, actual results could vary significantly. Article content Article content Article content Article content Article content Article content
Associated Press
12-05-2025
- Business
- Associated Press
AbTherx and Spice Biotechnologies Announce Multi-Program Antibody Discovery Collaboration
Immuno-oncology pioneer partners with AbTherx to build the next generation of immunotherapy drugs MOUNTAIN VIEW, CA / ACCESS Newswire / May 12, 2025 / AbTherx, Inc., a biotechnology company with innovative transgenic technologies that enable and accelerate antibody discovery, today announced a multi-program antibody discovery partnership with Spice Biotechnologies. The partnership will leverage AbTherx's suite of innovative Atlas™ Mouse technologies to deliver antibodies against targets selected by Spice Bio. AbTherx's antibody discovery platform is built on two decades of experience and utilizes evolutionary intelligence to identify diverse and developable human antibody sequences. This collaboration leverages AbTherx's novel, patent-pending Atlas Full Human Diversity Mouse, an updated industry standard with a strong IP position that generates fully human antibodies with the affinity and diversity required for efficient, successful drug development. It also utilizes the Binary Fixed Light Chain Transgenic Mouse which enables native-like IgG bispecific antibodies that improve manufacturability and developability. Through these innovative technologies and a deeply collaborative partnering model, AbTherx uniquely enables startups to efficiently manage resources, timelines, and technical risk. Spice Bio was founded by Alan J. Korman, a globally recognized leader in immunology and cancer research. With over 30 years of experience in drug development, Dr. Korman has shaped groundbreaking advancements in the field, most recently serving as an executive at Vir Biotechnology and Bristol Myers Squibb. Dr Korman led the discovery of a revolutionary approach to cancer immune therapy and immune checkpoint blockade, which has driven the development and approval of several groundbreaking oncology drugs. Working with AbTherx cofounders at Medarex and BMS, Dr. Korman found incredible success discovering and developing the world's first immune checkpoint inhibitors, YERVOY® (ipilimumab) and OPDIVO® (nivolumab). 'Over the last 20 years, the Spice Bio team has had an incredible track record of creating successful life-saving drugs in partnership with some of our AbTherx cofounders. Because of this long, productive history, we are particularly excited to partner with Dr. Korman again in his new venture to create the next generation of immunotherapy drugs,' said Justin Mika, Chief Executive Officer of AbTherx. 'AbTherx is uniquely positioned to lead the next wave of antibody therapeutics with continuous innovation in antibody discovery technology, deep experience in antibody discovery, and startup-friendly partnering models.' From top 10 pharmaceutical companies to virtual startups, leading organizations in antibody therapeutics have rapidly adopted the AbTherx platform, resulting in over 50 initiated programs across over a dozen partners in the past nine months. Under the terms of the agreement, Spice Bio has the right to develop and commercialize therapeutic antibodies resulting from the collaboration. AbTherx will receive research payments and is eligible to receive downstream clinical and commercial milestone payments, as well as royalties on net sales of products. About AbTherx AbTherx is advancing medicine with revolutionary technologies that accelerate and enable therapeutic antibody discovery. Through an exclusive license from Gilead Sciences, AbTherx has released Atlas™ Mice, a suite of novel transgenic technologies designed for unmatched performance and Freedom to Operate. For over 20 years, a core group of AbTherx's scientists have worked together to push the boundaries of antibody discovery technologies, resulting in more than 1,000 successful discovery campaigns and the development of 13 marketed therapeutics. AbTherx's industry-leading team creates transformative solutions to overcome the most demanding challenges in delivering innovative medicines. Committed to making its technologies accessible to all, AbTherx offers flexible partnering models that meet the needs of drug developers of all sizes. For more information, please visit Media Contact Stacey Borders [email protected] SOURCE: AbTherx, Inc. press release
